Fused ring derivative as A

1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof,

wherein,

1 or 2 of T 1 , T 2, T 3 and T 4 is N, the rest are independently CH;

each of R 1 is independently selected from H, halogen, OH, NH 2 or C 1-3 alkyl optionally substituted by 1, 2 or 3 R;

each of R 2 is independently selected from H, halogen, OH, NH 2 or C 1-3 alkyl optionally substituted by 1, 2 or 3 R;

n is selected from 0, 1, 2 and 3;

m is selected from 0, 1, 2 and 3;

ring A is selected from 6-10 membered aryl and 5-10 membered heteroaryl;

ring B is selected from phenyl and 5-6 membered heteroaryl;

R is selected from F, Cl, Br, I, OH, NH 2 and CN;

the “hetero” in the 5-6 membered heteroaryl and 5-10 membered heteroaryl are each independently selected from N, O, S, NH, —C(═O)—, —C(═O)O— and —C(═O)NH—;

the number of the heteroatom or heteroatom group is independently selected from 1, 2, 3 and 4.

2. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein each of R 1 is independently selected from H, F, Cl, Br, I, OH, NH 2 , Me and Et, wherein the Me and Et are optionally substituted by 1, 2 or 3 R.

3. The compound or the pharmaceutically acceptable salt thereof according to claim 2 , wherein each of R 1 is independently selected from H, F, Cl, Br, I, OH, NH 2 , Me, CF 3 and Et.

4. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein each of R 2 is independently selected from H, F, Cl, Br, I, OH, NH 2 and Me optionally substituted by 1, 2 or 3 R.

5. The compound or the pharmaceutically acceptable salt thereof according to claim 4 , wherein each of R 2 is independently selected from F, Cl, Br, I, OH, NH 2 and Me.

6. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein ring A is selected from phenyl, pyridyl, quinoxalyl, 1,2,3,4-tetrahydroquinolyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, benzo[d]isoxazolyl, [1 ,2,4]triazolo[4,3-a]pyridyl, 1H-benzo [d][1,2,3]triazolyl, cinnolinyl, quinazolinyl, quinolyl, isoquinolyl, imidazo[1,2-a]pyridyl, [1,2,4]triazolo[1,5-a]pyridyl, 1H-indazolyl and benzo[d]thiazolyl.

7. The compound or the pharmaceutically acceptable salt thereof according to claim 5 , wherein the structural unit

is selected from

8. The compound or the pharmaceutically acceptable salt thereof according to claim 3 , wherein the structural unit

is selected from

9. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein ring B is selected from phenyl, furanyl, thienyl and pyrazolyl.

10. The compound or the pharmaceutically acceptable salt thereof according to claim 9 , wherein the structural unit

is selected from

11. The compound or the pharmaceutically acceptable salt thereof according to claim 5 , wherein the structural unit

is selected from

12. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the structural unit

is selected from

13. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is selected from the group consisting of:

wherein,

R 1 and R 2 are as defined in claim 1 ;

ring C is selected from 5-6 membered heteroaryl and 5-6 membered heterocycloalkyl;

ring D is 5-6 membered heteroaryl;

the “hetero” in the 5-6 membered heteroaryl is selected from N, S and NH;

the “hetero” in the 5-6 membered heterocycloalkyl is NH;

the number of the heteroatom or heteroatom group is independently selected from 1, 2, 3 and 4.

14. The compound or the pharmaceutically acceptable salt thereof according to claim 13 , wherein the structural unit

is selected from

15. The compound or the pharmaceutically acceptable salt thereof according to claim 13 , wherein the structural unit

is selected from

16. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

17. A method for treating a disease related to A 2A receptor in a subject in need thereof, comprising administering a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 1 to the subject, wherein the disease related to A 2A receptor is a colon cancer.

18. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutical excipient.